VIH1 Stock Overview
A real estate holding company, develops, buys, holds, rents, and manages commercial real estate properties in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
VIB Vermögen AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €10.24 |
| 52 Week High | €15.20 |
| 52 Week Low | €6.80 |
| Beta | 0.92 |
| 11 Month Change | -14.09% |
| 3 Month Change | 45.87% |
| 1 Year Change | -16.48% |
| 33 Year Change | -75.36% |
| 5 Year Change | -63.43% |
| Change since IPO | 82.86% |
Recent News & Updates
Should You Think About Buying VIB Vermögen AG (ETR:VIH1) Now?
Oct 11
VIB Vermögen AG (ETR:VIH1) Shares Fly 26% But Investors Aren't Buying For Growth
Sep 20Recent updates
Should You Think About Buying VIB Vermögen AG (ETR:VIH1) Now?
Oct 11VIB Vermögen AG (ETR:VIH1) Shares Fly 26% But Investors Aren't Buying For Growth
Sep 20Concerns Surrounding VIB Vermögen's (ETR:VIH1) Performance
May 08When Should You Buy VIB Vermögen AG (ETR:VIH1)?
Dec 20Is VIB Vermögen (ETR:VIH1) Using Too Much Debt?
Jun 21Is Now The Time To Look At Buying VIB Vermögen AG (ETR:VIH1)?
May 30VIB Vermögen AG (ETR:VIH1) Shares Could Be 43% Below Their Intrinsic Value Estimate
Mar 29VIB Vermögen AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 18Is It Too Late To Consider Buying VIB Vermögen AG (ETR:VIH1)?
Feb 11Is It Too Late To Consider Buying VIB Vermögen AG (ETR:VIH1)?
Sep 06Is VIB Vermögen (ETR:VIH1) A Risky Investment?
Oct 15VIB Vermögen (ETR:VIH1) Has Compensated Shareholders With A Respectable 100% Return On Their Investment
Mar 11A Closer Look At VIB Vermögen AG's (ETR:VIH1) Impressive ROE
Feb 18
You Have To Love VIB Vermögen AG's (ETR:VIH1) Dividend
Jan 19Here's What VIB Vermögen AG's (ETR:VIH1) Shareholder Ownership Structure Looks Like
Dec 25Shareholders Of VIB Vermögen (ETR:VIH1) Must Be Happy With Their 94% Return
Dec 06A Closer Look At VIB Vermögen AG's (ETR:VIH1) Impressive ROE
Nov 18Shareholder Returns
| VIH1 | DE Real Estate | DE Market | |
|---|---|---|---|
| 7D | 1.0% | -2.2% | -1.3% |
| 1Y | -16.5% | 6.4% | 7.4% |
Return vs Industry: VIH1 underperformed the German Real Estate industry which returned 6.4% over the past year.
Return vs Market: VIH1 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| VIH1 volatility | |
|---|---|
| VIH1 Average Weekly Movement | 6.1% |
| Real Estate Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VIH1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: VIH1's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 40 | Dirk Oehme | www.vib-ag.de |
VIB Vermögen AG, a real estate holding company, develops, buys, holds, rents, and manages commercial real estate properties in Germany. The company’s real estate portfolio includes logistics and light industry properties, industrial real estate, shopping centers, and specialist retail parks, as well as commercial and service centers. It also manages properties of institutional investors.
VIB Vermögen AG Fundamentals Summary
| VIH1 fundamental statistics | |
|---|---|
| Market cap | €338.48m |
| Earnings (TTM) | €87.07m |
| Revenue (TTM) | €97.76m |
3.9x
P/E Ratio3.5x
P/S RatioIs VIH1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIH1 income statement (TTM) | |
|---|---|
| Revenue | €97.76m |
| Cost of Revenue | €19.25m |
| Gross Profit | €78.51m |
| Other Expenses | -€8.56m |
| Earnings | €87.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.63 |
| Gross Margin | 80.31% |
| Net Profit Margin | 89.06% |
| Debt/Equity Ratio | 101.3% |
How did VIH1 perform over the long term?
See historical performance and comparison